Researchers may be able to treat mesothelioma by targeting this specific part of the tumor; which could ultimately provide the medical community with a whole new approach to mesothelioma treatment.
San Diego, CA (PRWEB) March 31, 2015
According to an article published Jan. 14 2015 by Molecular Cancer Therapeutics titled, “CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma,” like Hodgkin disease and anaplastic large cell lymphoma, malignant mesothelioma tumors may contain CD30, a cytokine receptor belonging to the TNF superfamily, which regulates apoptosis.*
“The possible presence of CD30 in malignant mesothelioma tumors is a huge discovery,” said Melinda Helbock, Founder of The Law Office of Melinda J. Helbock A.P.C. “What this means is that researchers may be able to treat mesothelioma by targeting this specific part of the tumor; which could ultimately provide the medical community with a whole approach to mesothelioma treatment.”
The FDA approved the antibody-drug conjugate Adcetris (brentuximab vedotin) for the treatment of Hodgkin lymphoma and systematic anaplastic large cell lymphoma (ALCL) in 2011. According to the FDA, the drug works by using a combination of an antibody and a drug — the antibody directs the drug to a specific target on lymphoma cells known as CD30.**
“Now that we know some mesothelioma tumors may contain CD30, researchers may be able to use the same drugs they are using to target CD30 in lymphoma patients,” said Helbock. “This discovery is exciting and gives hope to the future of mesothelioma patients everywhere.”
About The Law Office of Melinda J. Helbock A.P.C.
The Law Office of Melinda J. Helbock A.P.C. is a personal injury law firm that represents the families of people with mesothelioma. The firm advocates for victims of asbestos exposure. For more information about the firm visit helbocklaw.com.